1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,320 | 1,350 | 17:19 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR2/3 INHIBITOR ABSK061 GRANTED ORPHAN DRUG DESIGNATION BY FDA FOR ACHONDROPLASIA | 6 | HKEx | ||
| Mo | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' IRPAGRATINIB COMBINED WITH TARGETED-IMMUNOTHERAPY COMPLETES FIRST PATIENT DOSING IN ... | 1 | HKEx | ||
| 11.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR FGFR2/3 INHIBITOR ABSK061 | 8 | HKEx | ||
| 09.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - THE LANCET PUBLISHES GLOBAL PHASE 3 MANEUVER STUDY RESULTS OF PIMICOTINIB | 1 | HKEx | ||
| 04.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' ORAL SMALL-MOLECULE KRAS G12D INHIBITOR ABSK141 COMPLETED FIRST PATIENT DOSING | 1 | HKEx | ||
| 03.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ... | - | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 02.03. | ABBISKO-B (02256): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; AND (2) CHANGE OF THE JOINT COMPANY SECRETARIES, AUTHORISED REPRESENTATIVE ... | 1 | HKEx | ||
| 11.02. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
| 11.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB COMPLETED FIRST U.S. PATIENT DOSING IN THE EXPANSION PART OF A GLOBAL PHASE I ... | 1 | HKEx | ||
| 10.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED FDA FAST TRACK DESIGNATION FOR HCC PATIENTS | 3 | HKEx | ||
| 13.01. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FDA ACCEPTANCE OF THE NDA FOR PIMICOTINIB FOR THE TREATMENT OF TGCT | 1 | HKEx | ||
| 13.01. | Abbisko Therapeutics Announces FDA Acceptance Of Pimicotinib NDA For Tenosynovial Giant Cell Tumor | 508 | AFX News | HONG KONG (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) for pimicotinib (ABSK021).... ► Artikel lesen | |
| 13.01. | Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor | 322 | PR Newswire | SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced... ► Artikel lesen | |
| 24.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE NMPA FOR ORAL SMALL MOLECULE KRAS G12D INHIBITOR ABSK141 | 5 | HKEx | ||
| 22.12.25 | Abbisko Therapeutics Co., Ltd.: Abbisko Therapeutics' CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor | 309 | GlobeNewswire (Europe) | Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world's first regulatory approval for pimicotinib, the first domestically... ► Artikel lesen | |
| 22.12.25 | ABBISKO-B (02256): INSIDE INFORMATION - ABBISKO THERAPEUTICS' CSF-1R INHIBITOR PIMICOTINIB APPROVED BY THE CHINA NMPA | 3 | HKEx | ||
| 16.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING OF ABSK061, FGFR2/3 INHIBITOR, FOR THE TREATMENT OF ACHONDROPLASIA | 1 | HKEx | ||
| 08.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS PRELIMINARY PHASE II RESULTS OF ORAL PD-L1 INHIBITOR ABSK043 COMBINED WITH EGFR ... | 1 | HKEx | ||
| 01.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE KRAS G12D INHIBITOR ABSK141 | 1 | HKEx | ||
| 17.11.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER STUDY OF PIMICOTINIB ... | 1 | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,69 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -5,18 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | +0,54 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,000 | +1,13 % | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | -5,89 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | +0,96 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| LENZ THERAPEUTICS | 10,480 | -8,79 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 7,940 | -7,08 % | Kyverna Therapeutics: Ein kommender Biotech-Star? | Die Aktie von Kyverna Therapeutics rückt zunehmend in den Blick von Investoren, die auf bahnbrechende CAR-T-Therapien im Autoimmunbereich setzen. Mit vielversprechenden Studiendaten und einer bevorstehenden... ► Artikel lesen | |
| NUVALENT | 94,82 | -2,31 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,050 (-3,65 %) liegt der Kurs bei 1,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.